tiprankstipranks
Trending News
More News >
MEDICLIN AG (DE:MED)
XETRA:MED
Advertisement

MEDICLIN (MED) AI Stock Analysis

Compare
1 Followers

Top Page

DE:MED

MEDICLIN

(XETRA:MED)

Rating:64Neutral
Price Target:
€3.00
▲(4.17%Upside)
The overall score reflects solid financial performance and attractive valuation, tempered by technical indicators suggesting stability but not momentum. The high leverage remains a key risk factor, and there is no recent earnings call or corporate events to affect the score.

MEDICLIN (MED) vs. iShares MSCI Germany ETF (EWG)

MEDICLIN Business Overview & Revenue Model

Company DescriptionMediclin (MED) is a leading healthcare services provider operating primarily in private healthcare facilities. The company offers a wide range of healthcare services, including hospital care, outpatient treatment, and specialist medical services. Mediclin is dedicated to delivering high-quality, patient-centered care and operates a network of hospitals and clinics equipped with state-of-the-art medical technology.
How the Company Makes MoneyMediclin makes money by providing healthcare services to patients who either pay out-of-pocket or through insurance providers. The company's revenue model is primarily based on charges for medical procedures, consultations, and hospital stays. Mediclin also generates income from partnerships with insurance companies and government health programs, which reimburse the company for services provided to insured or covered patients. Additionally, Mediclin may engage in strategic partnerships with medical equipment suppliers and pharmaceutical companies, enhancing its service offerings and operational efficiency.

MEDICLIN Financial Statement Overview

Summary
MEDICLIN shows improving profitability with a positive net profit margin and strong operational efficiency. However, the high debt-to-equity ratio indicates significant leverage risks, necessitating cautious debt management.
Income Statement
67
Positive
MEDICLIN has shown a consistent increase in gross profit margin, highlighting effective cost management, while the net profit margin improved notably in the latest period, turning positive after prior losses. Revenue growth has been moderate, and the recent EBIT and EBITDA margins are strong, indicating operational efficiency. However, past volatility in net income suggests some instability.
Balance Sheet
58
Neutral
The company's debt-to-equity ratio remains high, reflecting significant leverage which could pose financial risks. However, the improving return on equity and stable equity ratio suggest that MEDICLIN is effectively using its equity base to generate profits. The balance sheet shows a need for cautious debt management to ensure financial stability.
Cash Flow
73
Positive
Operating cash flow has been robust, consistently exceeding net income, indicating strong cash generation from operations. The free cash flow to net income ratio is favorable, showing efficient capital expenditure management. There is notable free cash flow growth, demonstrating improved liquidity, although careful monitoring is advisable to sustain this trend.
BreakdownDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue748.80M730.10M704.70M673.10M659.90M
Gross Profit623.00M594.60M571.90M551.00M547.20M
EBITDA106.41M101.27M91.80M85.43M76.84M
Net Income24.84M-10.78M9.44M1.46M-9.00M
Balance Sheet
Total Assets905.91M880.50M916.11M881.24M887.46M
Cash, Cash Equivalents and Short-Term Investments107.56M115.29M88.04M133.48M100.44M
Total Debt464.13M479.82M502.67M439.96M486.97M
Total Liabilities683.17M684.47M706.79M698.22M710.62M
Stockholders Equity222.51M195.92M209.21M183.28M177.16M
Cash Flow
Free Cash Flow35.88M40.43M8.62M64.96M92.91M
Operating Cash Flow80.57M78.00M34.64M81.97M118.69M
Investing Cash Flow-15.13M-9.51M-6.24M-7.09M-8.60M
Financing Cash Flow-73.16M-45.48M-56.17M-55.26M-46.50M

MEDICLIN Technical Analysis

Technical Analysis Sentiment
Negative
Last Price2.88
Price Trends
50DMA
2.96
Negative
100DMA
2.92
Negative
200DMA
2.74
Positive
Market Momentum
MACD
-0.02
Positive
RSI
45.46
Neutral
STOCH
55.56
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:MED, the sentiment is Negative. The current price of 2.88 is below the 20-day moving average (MA) of 2.96, below the 50-day MA of 2.96, and above the 200-day MA of 2.74, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.46 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DE:MED.

MEDICLIN Peers Comparison

Overall Rating
UnderperformOutperform
Sector (65)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
75
Outperform
€111.60M35.0518.60%0.76%-8.38%
68
Neutral
€255.89M15.8014.61%3.65%7.23%58.37%
66
Neutral
€789.87M20.243.09%0.85%12.23%-8.23%
65
Neutral
€6.48B19.09-1.30%2.17%-0.15%-41.88%
64
Neutral
€136.80M5.3212.45%1.39%1.26%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:MED
MEDICLIN
2.88
0.49
20.65%
DE:RHK
RHON-KLINIKUM AG
11.80
0.20
1.69%
DE:LIK
Limes Schlosskliniken AG
374.00
-6.00
-1.58%
DE:M12
M1 Kliniken AG
13.74
-1.23
-8.22%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jul 11, 2025